← Leaderboards
Su-Hsin Chang
Washington University
$3,347,018
Attributed
$5,170,971
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,666,005 · 3
AHRQ$504,966 · 1
By mechanism
U01$3,165,787 · 1
R01$1,080,843 · 1
K01$504,966 · 1
R21$419,375 · 1
Top collaborators
- Shiyi Wang6 shared
- Graham A Colditz3 shared
Most similar at Washington University
Same institution · by research overlap
- Richard D Rabbitt$13,364,972
- Peter Svend Hovmand$2,147,987
- Sean P. J. Whelan$36,954,740
- Enyo Ablordeppey$522,471
- Daved H Fremont$19,011,013
Others in their field
Top investigators on “Innovation”
- David R. Weir · University Of Michigan At Ann Arbor$382,307,654
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$319,874,172
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$311,654,401
- Richard A Gibbs · Baylor College Of Medicine$300,634,418
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Judith S. Currier · University Of California Los Angeles$271,752,220
Research focus
InnovationCostPreventionDiagnosisHematologic NeoplasmsMultiple MyelomaAdultObesitySolid NeoplasmAreaPreventPremalignantLifeMonoclonal Gammopathy Of Uncertain SignificancePrevention StrategyNeoplasmsClinical PracticeEconomic BurdenHealth DisparityIncidenceRacial DisparityEvidence BasePharmaceutical PreparationsCost-Effectiveness Evaluation
Grant awards (15)
Comparative modeling of multiple myeloma across myeloma continuum: prevention, treatment, and health drivers$624,497
U01 · FY2025 · CA · contact PI
Comparative modeling of multiple myeloma across myeloma control continuuum: prevention, treatment, and disparity reduction$462,628
U01 · FY2024 · CA · contact PI
Comparative modeling of multiple myeloma across myeloma control continuuum: prevention, treatment, and disparity reduction$632,304
U01 · FY2023 · CA · contact PI
Comparative modeling of multiple myeloma across myeloma control continuum: prevention, treatment, and disparity reduction$138,880
U01 · FY2023 · CA · contact PI
Comparative modeling of multiple myeloma across myeloma control continuuum: prevention, treatment, and disparity reduction$643,761
U01 · FY2022 · CA · contact PI
Addressing racial disparities in monoclonal gammopathy of undetermined significance and progression to multiple myeloma from a prevention perspective$360,281
R01 · FY2022 · CA · contact PI
Comparative modeling of multiple myeloma across myeloma control continuuum: prevention, treatment, and disparity reduction$663,717
U01 · FY2021 · CA · contact PI
Addressing racial disparities in monoclonal gammopathy of undetermined significance and progression to multiple myeloma from a prevention perspective$360,281
R01 · FY2021 · CA · contact PI
Addressing racial disparities in monoclonal gammopathy of undetermined significance and progression to multiple myeloma from a prevention perspective$360,281
R01 · FY2020 · CA · contact PI
MODELING THE COEXISTENCE OF CHRONIC DISEASES RELATED TO OBESITY$190,625
R21 · FY2018 · DK · contact PI
MODELING THE COEXISTENCE OF CHRONIC DISEASES RELATED TO OBESITY$228,750
R21 · FY2017 · DK · contact PI
OBESITY, COMORBIDITIES, AND ECONOMIC EVALUATIONS OF SURGICAL TREATMENTS OF OBESIT$136,661
K01 · FY2016 · HS · contact PI
OBESITY, COMORBIDITIES, AND ECONOMIC EVALUATIONS OF SURGICAL TREATMENTS OF OBESIT$133,397
K01 · FY2015 · HS · contact PI
OBESITY, COMORBIDITIES, AND ECONOMIC EVALUATIONS OF SURGICAL TREATMENTS OF OBESIT$130,207
K01 · FY2014 · HS · contact PI
OBESITY, COMORBIDITIES, AND ECONOMIC EVALUATIONS OF SURGICAL TREATMENTS OF OBESIT$104,701
K01 · FY2013 · HS · contact PI